1. Home
  2. NUVB vs WVE Comparison

NUVB vs WVE Comparison

Compare NUVB & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$6.01

Market Cap

2.9B

Sector

Health Care

ML Signal

HOLD

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

HOLD

Current Price

$13.86

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUVB
WVE
Founded
2018
2012
Country
United States
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
3.0B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
NUVB
WVE
Price
$6.01
$13.86
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
16
Target Price
$10.44
$29.94
AVG Volume (30 Days)
6.3M
4.1M
Earning Date
03-05-2026
03-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$26,748,000.00
$109,230,000.00
Revenue This Year
$616.63
N/A
Revenue Next Year
$202.59
$16.20
P/E Ratio
N/A
N/A
Revenue Growth
1137.19
103.75
52 Week Low
$1.54
$5.28
52 Week High
$9.75
$21.73

Technical Indicators

Market Signals
Indicator
NUVB
WVE
Relative Strength Index (RSI) 29.46 45.52
Support Level $6.07 $13.72
Resistance Level $6.63 $15.97
Average True Range (ATR) 0.53 1.34
MACD -0.39 -0.50
Stochastic Oscillator 11.03 9.08

Price Performance

Historical Comparison
NUVB
WVE

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Share on Social Networks: